ABIVAX Société Anonyme (EPA:ABVX)
France · Delayed Price · Currency is EUR | Market Cap | 10.57B +2,422.8% |
| Revenue (ttm) | 4.92M -59.8% |
| Net Income | -332.20M |
| EPS | -4.52 |
| Shares Out | 86.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,898 |
| Open | 124.10 |
| Previous Close | 122.60 |
| Day's Range | 120.60 - 125.00 |
| 52-Week Range | 6.89 - 139.00 |
| Beta | -0.21 |
| Analysts | Buy |
| Price Target | 130.06 (+5.83%) |
| Earnings Date | Sep 21, 2026 |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]
Financial Performance
In 2025, ABIVAX Société Anonyme's revenue was 4.57 million, a decrease of -63.22% compared to the previous year's 12.43 million. Losses were -336.10 million, 90.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ABVX stock is "Buy." The 12-month stock price target is €130.06, which is an increase of 5.83% from the latest price.
News
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its CEO told CNBC on Friday. The French biotech has been under ...
Abivax price target raised to $175 from $165 at Piper Sandler
Piper Sandler raised the firm’s price target on Abivax (ABVX) to $175 from $165 and keeps an Overweight rating on the shares. The firm is raising its ulcerative colitis obefazimod…
Abivax: Wall Street Catches Up to the Data
Shares of Abivax NASDAQ: ABVX were up more than 40% in the month ending July 6, after the company announced positive results from its late-stage (Phase 3) trial of its lead candidate, Obefazimod, whic...
Abivax Announces Closing of $920 Million Public Offering
Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a cl...
European Markets Rise to Record Highs Amid Optimism; Abivax SA (ABVX) Surges
European Markets Rise to Record Highs Amid Optimism; Abivax SA (ABVX) Surges
Abivax price target raised to $155 from $135 at Truist
Truist raised the firm’s price target on Abivax (ABVX) to $155 from $135 and keeps a Buy rating on the shares. ollowing maintenance Part 2 data, discussions with Abivax management…
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
Shares rose 5% after the biotech moved to bolster its balance sheet through an upsized stock offering, signaling investor appetite in the wake of positive clinical-trial data.
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax nears $11 billion valuation after fundraising eases M&A pressure
Abivax SA raised $800 million in an expanded share sale on Wednesday after strong investor demand, valuing the French biotechnology company at nearly $11 billion and easing pressure to pursue a near...
Abivax (ABVX) Raises $800M in Upsized Public Offering
Abivax (ABVX) Raises $800M in Upsized Public Offering
Abivax Prices Oversubscribed $800M ADS Offering To Support Obefazimod Development
(RTTNews) - Abivax SA (ABVX) announced the pricing of an upsized and oversubscribed public offering of 6.4 million American Depositary Shares (ADSs) at $125.00 per ADS, raising approximately $800 mill...
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
ABIVAX Announces Pricing Of $800 Mln Offering Of ADS
(RTTNews) - Wednesday, ABIVAX Société Anonyme (ABVX) announced the pricing of an underwritten public offering of 6.4 million American Depositary Shares or ADSs, each representing one ordinary share, 0...
Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”)...
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax Requests Trading Halt On Euronext Paris For $600 Mln ADS Offering
(RTTNews) - Abivax SA (ABVX, ABVX.PA), a clinical-stage biotechnology company, announced on Wednesday that trading of its shares on the Euronext Paris market will be temporarily halted, at the company...
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Compa...
Top Biotech Gainers: ABVX Soars On UC Trial Data, PMN Eyes Alzheimer's Catalyst, TRAX In Focus
(RTTNews) - Today's top gainers in the biotech space include Cuprina, which recently received FDA clearance for its maggot-based wound treatment; ABIVAX, following encouraging results from an ulcerati...
Abivax (ABVX) Launches $600M Public Offering for Drug Development
Abivax (ABVX) Launches $600M Public Offering for Drug Development
Abivax (ABVX) Initiates $600M Public Offering for Growth Initiatives
Abivax (ABVX) Initiates $600M Public Offering for Growth Initiatives
Abivax (ABVX) Stock Surges After Positive Obefazimod Safety Data
Abivax (ABVX) Stock Surges After Positive Obefazimod Safety Data
Abivax announces $600M ADS offering
Abivax (ABVX) SA announced the launch of an underwritten public offering of approximately $600M of its American Depositary Shares, or ADSs, each representing one ordinary share of Abivax. All ADSs…
Abivax Announces Launch of Public Offering of American Depositary Shares
Abivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or t...
US Market, Top Gainers: Abivax SA jumps 38.6% as top after-close gainer on July 1
US equities closed broadly higher on July 1, with the S&P 500 surging 1.82%, the Nasdaq soaring 2.45% and the Dow climbing 1.26%, while individual stocks saw considerably sharper swings.…
Abivax upgraded to Buy at Jefferies after additional ABTECT data
As previously reported, Jefferies upgraded Abivax (ABVX) to Buy from Hold with a price target of $158, up from $108, arguing that the ABTECT part two update “appropriately addresses the…